NCT04351100|Completed
Loading search results
Sponsor study identifier
observational
34
1 country
1
Study Start
October 1, 2019
Actual (reported)Primary Completion
July 31, 2020
Actual (reported)Study Completion
July 31, 2020
Actual (reported)Dry eyes is multi-factorial disease which inflammation play etiological role. Diacerein is drug which has anti-inflammatory effect by antagonist Interleukin-1, decrease Interleukin-1 receptor, increase Interleukin-1 Receptor antagonist. This observational study enrolled participants who going to take diacerein for osteoarthritis, measure corneal staining score, Ocular surface disease index score, Tear Osmolarity, Tear break up time, Schirmer 1 test, Interleukin-1 Receptor antagonist, Interleukin-1 alpha, Interleukin-1 beta level in tear at the time of enrollment and after 2 months.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 31, 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 1, 2019
Actual (reported)April 10, 2020
Actual (reported)April 17, 2020
Actual (reported)July 31, 2020
Actual (reported)July 31, 2020
Actual (reported)Corneal staining score change from baseline at 2 months
Stain Cornea with Fluorescine, count and score staining at the cornea according to National eye institute : score 0-15 (0=no staining)
At the time of enrollment and 2 months
Ocular surface disease index score
At the time of enrollment and 2 months
Tear Osmolarity
At the time of enrollment and 2 months
Osteoarthritis and dry eye patients treated with Diacerein
Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients diagnosed with osteoarthritis that prescribed Diacerein at out-patient clinic, Department of Orthopedic, King Chulalongkorn Memorial Hospital
Faculty of medicine, Chulalongkorn university
Bangkok, 10330, Thailand
Tears within Schirmer paper
Ngamjit Kasetsuwan
Department of Ophthalmology, Chulalongkorn University
34 participants (actual enrollment reported by the registry).
First Submitted
April 10, 2020
First Posted
April 17, 2020
Study Start
October 1, 2019
Actual (reported)Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)
Tear break up time
At the time of enrollment and 2 months
Schirmer 1 test
At the time of enrollment and 2 months
Interleukin-1 receptor antagonist, Interleukin-1 alpha, Interleukin-1 beta level in tear
At the time of enrollment and 2 months
Contact the study team to confirm eligibility.
Primary Completion
July 31, 2020
Actual (reported)Study Completion
July 31, 2020
Actual (reported)Last Updated
August 10, 2021
Record last verified: 2021-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: